Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Hansson

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
Human Genomics|August 21, 2019
Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genesMolly Went, Ben Kinnersley, Amit Sud, et al.
Haematologica|September 14, 2019
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 studyLene Kongsgaard Nielsen, Claudia Stege, Birgit Lissenberg-Witte, et al.
Nature Communications|May 27, 2015
Variants in ELL2 influencing immunoglobulin levels associate with multiple myelomaBhairavi Swaminathan, Guðmar Thorleifsson, Magnus Jöud, et al.
Cancer Cell|April 16, 2015
Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivoAli Roghanian, Ingrid Teige, Linda Mårtensson, et al.
Nature Genetics|June 20, 2017
Identification of sequence variants influencing immunoglobulin levelsStefan Jonsson, Gardar Sveinbjornsson, Aitzkoa Lopez de Lapuente Portilla, et al.
Blood|January 24, 2016
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myelomaSonja Zweegman, Bronno van der Holt, Ulf-Henrik Mellqvist, et al.
The New England Journal of Medicine|December 9, 2025
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple MyelomaLuciano J Costa, Nizar J Bahlis, Aurore Perrot, et al.
Nature Communications|August 5, 2024
Deciphering the genetics and mechanisms of predisposition to multiple myelomaMolly Went, Laura Duran-Lozano, Gisli H Halldorsson, et al.
Blood Cancer Journal|January 4, 2019
Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiologyMolly Went, Amit Sud, Helen Speedy, et al.
Nature Communications|July 2, 2016
Genome-wide association study identifies multiple susceptibility loci for multiple myelomaJonathan S Mitchell, Ni Li, Niels Weinhold, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Human Genomics|August 21, 2019
Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genesMolly Went, Ben Kinnersley, Amit Sud, et al.
Haematologica|September 14, 2019
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 studyLene Kongsgaard Nielsen, Claudia Stege, Birgit Lissenberg-Witte, et al.
Nature Communications|May 27, 2015
Variants in ELL2 influencing immunoglobulin levels associate with multiple myelomaBhairavi Swaminathan, Guðmar Thorleifsson, Magnus Jöud, et al.
Cancer Cell|April 16, 2015
Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivoAli Roghanian, Ingrid Teige, Linda Mårtensson, et al.
Nature Genetics|June 20, 2017
Identification of sequence variants influencing immunoglobulin levelsStefan Jonsson, Gardar Sveinbjornsson, Aitzkoa Lopez de Lapuente Portilla, et al.
Blood|January 24, 2016
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myelomaSonja Zweegman, Bronno van der Holt, Ulf-Henrik Mellqvist, et al.
The New England Journal of Medicine|December 9, 2025
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple MyelomaLuciano J Costa, Nizar J Bahlis, Aurore Perrot, et al.
Nature Communications|August 5, 2024
Deciphering the genetics and mechanisms of predisposition to multiple myelomaMolly Went, Laura Duran-Lozano, Gisli H Halldorsson, et al.
Blood Cancer Journal|January 4, 2019
Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiologyMolly Went, Amit Sud, Helen Speedy, et al.
Nature Communications|July 2, 2016
Genome-wide association study identifies multiple susceptibility loci for multiple myelomaJonathan S Mitchell, Ni Li, Niels Weinhold, et al.
Pageof 9